NEW INDICATIONS! Sogroya® is the first and only once-weekly growth hormone treatment approved for children 2.5 years of age and older who are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years, are not growing and have Noonan Syndrome (NS), and have Idiopathic Short Stature (ISS). Ask your doctor for more information. Please click here for Sogroya Prescribing Information.
Once-Weekly Sogroya®
FREEDOM FROM DAILY INJECTIONS
Sogroya® is the first once-weekly growth hormone treatment for children (2.5 years and older) and adults with growth hormone deficiency (GHD), and the first and only for children 2.5 years of age and older who are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years, are not growing and have Noonan Syndrome (NS), and have Idiopathic Short Stature (ISS).
Talk to your doctor about Sogroya®: the most prescribed once-weekly GH treatmenta
Where would you like to go now? You can...
See long-term results & a safety profile for pediatric patients with GHD
Discover what a once-weekly GH treatment has to offer
View insurance: highest commercial preferred access for any long-acting GH treatmentb
Hear from families who chose to treat with Sogroya®
aBased on data from Komodo Sentinel as of February 2026.
bCoverage status does not imply product endorsement.
Sogroya®: 10 years of combined long-term exposure in pediatric GHD patients
Based on combined data from the REAL3, dose-finding, phase 2 trial, and REAL4 phase 3 trial in GHD pediatric patients.c
cREAL3 was a phase 2, randomized, open-label, dose-finding trial investigating the efficacy and safety of somapacitan vs daily GH in children with GHD. A total of 43 out of the 59 participants (aged 2.5 to 10 years) completed the long-term safety extension period (Week 364; Year 7), 10 of whom received daily GH from the start of the trial up to Week 156, and then switched to somapacitan 0.16 mg/kg/wk (switched group), and 33 of whom received somapacitan throughout the trial. REAL4 was a randomized, multi-national, open-label, active-controlled, parallel-group, phase 3 trial. The REAL4 main trial phase (Week 0 to Week 52) was followed by an ongoing 3-year, single-group, safety extension phase (Week 52 to Week 208) featuring 194 patients of whom 188 completed 156 weeks of treatment.
The Sogroya® pen: easy to use and based on the FlexPro® you knowd
The Sogroya® pen is ready to use, prefilled, and doesn’t require cartridges or preparation of the medicine. So, which device do you think is preferred by patients and caregivers alike?
dIn a randomized, crossover device preference and handling study of the Sogroya® pen in 33 adolescents aged 10-17 with growth-related disorders and 37 caregivers aged 18 and older, 99% (69) of participants found the Sogroya® pen easy or very easy to use. After training, users performed simulated injections into a pad or mannequin and then completed the Device Handling and Preference Assessment Questionnaire (DHPAQ).
Starting treatment or switching to Sogroya®?
Sogroya® has the highest commercial preferred access with an 91% approval rate among long-acting GH treatments.
The first once-weekly growth hormone (GH) treatment for children and adults with GHD, Sogroya® has preferred coverage with CVS Caremark®, Optum, FEP, TRICARE®, Texas Medicaid, MedImpact/Elixir, and Aetna®. Get more information about support programs as you begin your GH journey.e
eIndividual benefit designs and individual coverage may vary. Because many health plans offer more than one formulary, check directly with your health plan to confirm coverage.
Actor portrayal
Actor portrayal
Are you an adult living with AGHD?
Leave the once-daily baggage behind with Sogroya®. The first once-weekly treatment for adult growth hormone deficiency (AGHD).
Already on Sogroya®?
Get help planning injections
The Sogroya® Smart Scheduler will help you manage your injection days, including split doses.
Personalize your pen
Let’s make dose day more fun! With tons of charms and stickers to choose from, kids can express themselves with their pen.
Updates and helpful information
Tips and suggestions
Support, including patient resources